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Introduction {#sec005}
============

The existence of intranuclear inclusions (NI) in many normal and neoplastic tissues has been known for a long time, in diabetic patients \[[@pone.0226199.ref001]\] in hepatocytes \[[@pone.0226199.ref002], [@pone.0226199.ref003]\] and particularly in thyroid carcinoma \[[@pone.0226199.ref004], [@pone.0226199.ref005]\], where its presence is one of the diagnostic criteria for papillary thyroid carcinoma \[[@pone.0226199.ref004], [@pone.0226199.ref005]\]. Ultrastructural studies of hepatocytes revealed that the inclusions contained cytoplasmic structures, often with degenerative changes. This supports the assumption that the NI are entirely separated from the cytoplasm \[[@pone.0226199.ref006]\]. Two morphologically different types of NI can be distinguished. First, inclusions which are due to the accumulation of virus particles or glycogen and which are not membrane-bounded, and second, inclusions that are bounded by a nuclear membrane \[[@pone.0226199.ref007], [@pone.0226199.ref008]\]. Meningiomas showed NI resembling autophagic vacuoles with lysosomal bodies suggesting an active macroautophagy process \[[@pone.0226199.ref009]\].

In thyroid carcinoma (TC), however, NI were seen as invaginations of the cytoplasm, i.e. bordered by the nuclear membrane with a considerable variety of size and shape even in the same tumor \[[@pone.0226199.ref010]\]. Also, occasionally "nuclear bubbles", fixation artifacts, can be detected in TC which are distinguishable from inclusions by the lack of a surrounding nuclear envelope \[[@pone.0226199.ref010], [@pone.0226199.ref011]\]. There are several ultrastructural studies of inclusions in thyroid cancer \[[@pone.0226199.ref005], [@pone.0226199.ref012]--[@pone.0226199.ref014]\]. Söderström et al observed electron-dense spherical bodies in NI; Carcangiu and Oyama et al revealed that these inclusions contained cell organelles and were surrounded by a nuclear envelope. Oyama et al documented that these inclusions contained enlarged RER, many Golgi vesicles, small vesicles (diameter of 300--500 nm) and fragments of mitochondria or crumpled membranes caused by increased protein synthesis and/or protein accumulation. Autophagosomes with such crumpled membranes and abundant heterolysosomes, indicating degradation inside NI, were also detected \[[@pone.0226199.ref005]\]; Söderström et al also observed small vesicles in the inclusions \[[@pone.0226199.ref014]\]. Kaneko et al revealed that NI and nuclear grooves both were formed by the nuclear membranes \[[@pone.0226199.ref013]\].

Although there are many observations regarding NI, there is no study that addresses the issue of whether these NI have a biological function. Therefore, we have recently investigated NI in hepatocellular carcinoma and have shown that they contain autophagy-associated proteins and correlate with prolonged survival \[[@pone.0226199.ref008]\]. These inclusions were located entirely within the nucleus and could be developed by occlusion of cytoplasmic invagination. Since NI play an important role in the diagnosis of thyroid carcinomas, we now examined the inclusions in thyroid carcinoma in respect to a possible function. In addition, it is also documented that strong immunopositivity for ß-catenin was detected within NI in 83% of PTCs \[[@pone.0226199.ref015]\]. Thus, we performed 3D reconstruction of the nuclei to investigate the development of the inclusions in thyroid carcinoma. In order to elucidate whether autophagy-associated proteins \[[@pone.0226199.ref016]\] are detectable in the inclusions, we examined them immunohistochemically for the presence of p62/sequestosome1, ubiquitin, LC3B, cathepsin B and cathepsin D.

The detection of *BRAF* Mutation is an important diagnostic tool for papillary thyroid cancer \[[@pone.0226199.ref017]\]. BRAF activation is involved in many biological processes including cell proliferation and autophagy \[[@pone.0226199.ref018], [@pone.0226199.ref019]\]. The aims of the present study were to describe in detail NI in thyroid carcinoma, clarify their biological function and to investigate a possible connection to the occurrence of *BRAF*^*V600E*^ mutation.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

For this study, 107 tissue samples of thyroid carcinoma (71 female, 36 male; mean age 48 years, range 9--84 years), including all major subtypes, were obtained retrospectively from the archives of the Institute of Pathology, University Hospital of Essen, Germany. In all cases uniformly processed formalin-fixed and paraffin-embedded (FFPE) material was available. Slides were prepared and stained with HE (haematoxylin and eosin) according to institutional standards. The tumors were diagnosed according to the current WHO-criteria \[[@pone.0226199.ref020]\] and classified according to the TNM-system (8th edition). [Table 1](#pone.0226199.t001){ref-type="table"} provides details on patient and tumor characteristics.

10.1371/journal.pone.0226199.t001

###### Patient's characteristics: Number of cases, mean age and sex of each group of patients.

![](pone.0226199.t001){#pone.0226199.t001g}

  Tumor type                 Number    Mean age (range)   Male:female
  -------------------------- --------- ------------------ -------------
  ATC                        n = 10    69 (55--84)        4:6
  PDTC                       n = 19    48 (13--80)        7:12
  MTC                        n = 10    48 (12--63)        4:6
  FTC                        n = 16    50 (9--76)         6:10
  NIFTP                      n = 9     48 (28--68)        2:7
  PTC (n = 43)                                            
  \- Solid variant           n = 4     32 (19--58)        0:4
  \- Tall cell variant       n = 17    49 (10--77)        5:12
  \- Follicular variant      n = 9     42 (25--57)        3:6
  \- Conventional variant    n = 11    43 (18--75)        5:6
  \- Hobnail variant         n = 1     28                 0:1
  \- Columnar cell variant   n = 1     33                 0:1
  Total                      n = 107   48 (9--84)         36:71

*Abbreviations*: ATC = undifferentiated (anaplastic) thyroid carcinoma; PDTC = poorly differentiated thyroid carcinoma; MTC = medullary thyroid carcinoma; FTC = follicular thyroid carcinoma; NIFTP = non-invasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid carcinoma; n = number.

Written informed consent was obtained from every patient. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committee (Institutional Review Board) of the University Hospital Essen (reference number: 16-6917-BO).

Tissue microarray construction {#sec008}
------------------------------

To study the expression of selected candidate proteins by immunohistochemistry we used tissue microarrays (TMAs). TMA construction was performed as previously described \[[@pone.0226199.ref008]\]. In the case of histologically obvious tumor heterogeneity, areas with lowest degree of differentiation were selected. Three 1-mm-thick tissue cores were taken from each thyroid carcinoma specimen. Each TMA contained three corresponding tumor-free thyroid tissue cores as controls and cores with myocardium tissue for TMA orientation. Additionally, HE-staining was performed from each TMA.

Immunohistochemistry {#sec009}
--------------------

1 to 2μm thick sections from FFPE tissue blocks were cut, dewaxed and pretreated. Immunohistochemical (IHC) stainings were performed with an automated staining device (Dako Autostainer, Dako, Glostrup, Denmark). IHC was carried out with antibodies against ubiquitin (\#Z0458, Dako), p62 (\#sc-28359, Santa Cruz, CA, USA), LC3B (\#0231--100, Nano Tools, Hamburg, Germany), cathepsin B (\#sc-6490-R, Santa Cruz), cathepsin D (\#sc-6486, Santa Cruz), lamin AC (\#2032, Cell Signaling, Danvers, MA, USA) and BRAF^V600E^ (\#ab228461, Abcam, Cambridge, UK). Detailed information on used antibodies and staining protocols are given in [S1 Table](#pone.0226199.s002){ref-type="supplementary-material"}. Negative controls were included in every run. For negative controls, slides were incubated with non-immune immunoglobulin instead of the primary antibody, carried out in the same concentration as the primary antibody. For positive controls, tumor cases that presented with a specific staining during antibody establishment were included in every subsequent run.

One investigator (DW) evaluated the HE stained slides and the immunohistochemical stains. NI were counted in all three tissue cores per case and total numbers were normalized to one square millimeter.

Next generation sequencing (NGS) {#sec010}
--------------------------------

FFPE tumor tissue of all cases was characterized by NGS with the Illumina MiSeq sequencer (Illumina, San Diego, CA, USA) following manufacturer's instructions. After deparaffinization of FFPE tissue, DNA was extracted using an automated system and kit (Maxwell/RSC DNA FFPE Kit, Promega, Fitchburg, WI, USA) according to the manufacturer's instructions. DNA concentrations were determined by Qubit^®^ 2.0 Fluorometer dsDNA HS assay kit (LifeTechnologies, CA, USA). All samples showed a concentration between 0.5--70 ng/μl.

A total amount of 45 ng DNA was used to perform multiplex-PCR (four primer pools with 10 ng/primer pool+ 10% excess). Multiplex PCR and purification were performed with the GeneRead DNAseq Custom Panel V2, GeneRead DNAseq Panel PCR Kit V2 (Qiagen, USA) and Agencourt^®^ AMPure^®^ XP Beads (Beckmann, USA), followed by measurement of total DNA amount by Qubit^®^ 2.0 Fluorometer dsDNA HS assay kit. The library preparation was performed with NEBNext Ultra DNA Library Prep Set for Illumina (New England Biolabs, MA, USA), according to the manufacturer's recommendations by using 24 different indices per run. The pooled library was sequenced on MiSeq (Illumina; 2 × 150 bases paired-end run) and analyzed by Biomedical Genomics Workbench (CLC Bio, Qiagen, USA).

For targeted sequencing a customized thyroid-panel was designed containing regions of interest. The thyroid-panel contained 23 genes of the Wnt pathway and hot-spot regions out of the *BRAF*, *KRAS* and *NRAS* genes. The analyzed genes and exons are listed in [S2 Table](#pone.0226199.s003){ref-type="supplementary-material"}. The regions were covered by a total of 1135 amplicons. In all runs an average coverage of approximately 2500x was obtained.

Transmission electron microscopy (TEM) {#sec011}
--------------------------------------

Fresh tissue from thyroid biopsy of a representative thyroid carcinoma patient was fixed in 2% glutaraldehyde in 0.1 M cacodylate buffer (cb), pH 7.3, for 4 h at room temperature (RT), washed in cb, post-fixed with 1% osmium tetroxide in cb, dehydrated in a graded series of alcohol and embedded in epoxy resin. We stained semi-thin sections with basic fuchsin and methylene blue in order to define blocks of adequate quality. Ultrathin sections from selected blocks were mounted on copper grids, double-stained with uranyl acetate (1%) and lead citrate (0.4%) and examined using a Zeiss TEM 902A (Zeiss, Oberkochen, Germany). For digital image acquisition, we used an attached Morada slow-scan-CCD camera and the ITEM 5.2 software (both Olympus Soft-imaging-Systems, Münster, Germany).

3D imaging of immunofluorescence-labeled isolated nuclei {#sec012}
--------------------------------------------------------

In order to visualize the location of the inclusion within the nucleus, 3D imaging on isolated complete nuclei was performed. We studied the spatial position of the inclusion in relation to the nucleus by scanning the whole nucleus. For immunofluorescence tumor cell nuclei of two representative thyroid patients were isolated. Paraffin sections (60 μm thick) were placed in a 1.5 ml reaction tube and deparaffinized in xylene. After removing the supernatant, the pellet was rehydrated in 99%, 96% and 70% ethanol and supernatant was discarded. To remove residual ethanol, the pellet was washed in Target Retrievel Solution pH9 (\#S2367, Dako), centrifuged and the supernatant was removed. The pellet was resuspended in 400 μl Target Retrievel Solution pH9 and disrupted by a homogenizer. Heat-induced epitope retrievel (HIER) was performed by heating the suspension at 98 °C in a water bath for 60 min. After that, the reaction tube with the suspension was cooled at RT for 30 min. The protocol describing the isolation of nuclei with subsequent immunostaining is available at: <http://dx.doi.org/10.17504/protocols.io.78phrvn>. The suspension was centrifuged, supernatant was discarded and the pellet was washed with washing buffer (\#WL583C2500; DCS, Hamburg, Germany). After centrifugation, the supernatant was discarded and the pellet was equilibrated in a antibody diluent composite with Dako REAL Antibody Diluent (\#S2022, Dako) containing additionally 2% BSA and 0.5% saponin for the permeabilization of the cells for 30 min at RT. Immunostaining of the cells was performed in the 1.5 ml reaction tube by incubation with the primary rabbit monoclonal antibody against lamin AC (\#ab193904, Abcam) diluted 1:50 in the antibody diluent composite overnight at 4 °C. Cells were centrifuged, washed and incubated with the secondary antibody Alexa Fluor 488-conjugated donkey anti-rabbit IgG (\#A21206, Thermo Fisher Scientific, Waltham, MA, USA) in a dilution of 1:100 in the antibody diluent composite for 60 min at RT ([S3 Table](#pone.0226199.s004){ref-type="supplementary-material"}). After nuclear staining with DAPI (Sigma-Aldrich, Steinheim, Germany), cells were mounted in anti-quenching medium (Vectashield; Vector Laboratories, Inc. Burlingame, CA, USA). Microscopy was carried out using a Leica TCS SP8 STED confocal microscope (Leica Microsystems, Illinois, USA) and images were analyzed with the Application Suite X software (Leica Microsystems). For 3D reconstruction based on sectional images we used the open source software Fiji (ImageJ; [www.fiji.sc](http://www.fiji.sc)) and z-stacks were deconvolved with the Huygens Professional software (Scientific Volume Imaging; [www.svi.nl/ContactSVI](http://www.svi.nl/ContactSVI)).

Double-labeling immunofluorescence studies of tissue sections {#sec013}
-------------------------------------------------------------

### Analysis of autophagy-associated proteins by double-immunofluorescence {#sec014}

We performed double-immunofluorescence staining for LC3B with ubiquitin, p62 with ubiquitin and LC3B with p62 to investigate a possible co-localization of them in the same inclusion. FFPE tissue sections were cut at 1 μm, dewaxed, rehydrated and pretreated with Target Retrieval Solution (Dako) at pH 9.0 for 20 min at 97 °C. We used the primary antibodies anti-LC3B (\#3868, Cell Signaling), anti-p62 (\#BWL PW9860, Enzo, Life Sciences, NY, USA), anti-p62 (\#Sc-28359, Santa Cruz) and anti-ubiquitin (\#NB300-130, Novus, Littleton, CO). The secondary antibodies used were Cy3-conjugated goat anti-rabbit IgG (H+L) (\#111-166-045, Dianova, Hamburg, Germany) and Alexa Fluor 488-conjugated goat anti-mouse IgG1 (\#A21121, Thermo Fisher Scientific). Double-labeling for LC3B with ubiquitin: Anti-LC3B antibody (1:20) was labeled with Cy3 (1:100) and anti-ubiquitin antibody (1:1000) with Alexa Fluor 488 (1:100), each incubation was performed twice for 30 min at RT. Double-labeling for p62 with ubiquitin: Anti-p62 (Enzo) antibody (1:500) was labeled with Cy3 (1:800) and anti-ubiquitin antibody (1:1000) with Alexa Fluor 488 (1:100). Double-labeling for LC3B with p62: Anti-LC3B antibody was labeled with Cy3 and anti-p62 (Santa Cruz) antibody with Alexa Fluor 488 (for details, see [S4 Table](#pone.0226199.s005){ref-type="supplementary-material"}). DNA was stained with DAPI and images were analyzed as described above.

### Double-immunofluorescence labeling of *BRAF^V600E^* and autophagy-associated proteins {#sec015}

To analyze whether mutant BRAF is co-localized with autophagy-associated proteins anti-BRAF^V600E^ (\#ab228461, Abcam) was double-labeled with either anti-LC3B (\#3868, Cell Signaling) or anti-p62 (\#BWL PW9860, Enzo) or with anti-ubiquitin (\#Z0458, Dako). FFPE tissue sections were treated as described above. We performed fluorochrome labeling of BRAF^V600E^ with the VectaFluor^™^ Excel Amplified DyLight^®^ 594 Anti-Mouse IgG Kit (\#DK-2594, Vector Laboratories). The Donkey Anti Rabbit Alexa Fluor 488 (\#A21206, Thermo Fisher Scientific) was used for fluorochrome labeling of p62, LC3B and ubiquitin.

Briefly, tissue sections were incubated 2x with anti-BRAF^V600E^ antibody (1:100) for 60 min and afterwards with DyLight594 (ready to use) for 30 min at RT. Double-labeling of BRAF^V600E^ with LC3B: sections were incubated with LC3B (1:100) and afterwards with Alexa Fluor 488 (1:100). Double-labeling of BRAF^V600E^ with p62: sections were incubated with p62 (1:250) and afterwards with Alexa Fluor 488 (1:100). Double-labeling of BRAF^V600E^ with ubiquitin: sections were incubated with ubiquitin (1:500) and afterwards with Alexa Fluor 488 (1:100); detailed information is provided in [S5 Table](#pone.0226199.s006){ref-type="supplementary-material"}. DAPI was used for DNA staining and images were analyzed as described above.

Statistical analysis {#sec016}
--------------------

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS 24.0, Chicago, IL, USA). Relationships between categorical parameters were investigated using the two-sided Fisher's exact test. Further, we used Mann--Whitney *U*-test to assess whether the *BRAF* mutational status correlates firstly with the number of NI and secondly with the number of inclusions positively stained for autophagy-associated proteins; p ≤ 0.05 was defined as statistically significant.

Results {#sec017}
=======

Characterization of the intranuclear inclusions (NI) {#sec018}
----------------------------------------------------

We considered an inclusion as positive if it was delimited by a lamin AC (nuclear membrane marker) stained intact membrane and completely closed. Study of three 1-mm-thick tissue cores of each patient in the TMA sections of the thyroid cohort revealed evaluable material for lamin AC staining in 99/107 cases. Briefly, 29% of the thyroid carcinoma cases harbored at least one lamin AC positive inclusion. The maximum number of NI per case was 114/mm^2^ ([Table 2](#pone.0226199.t002){ref-type="table"}). HE-staining (left image, [Fig 1A](#pone.0226199.g001){ref-type="fig"}) demonstrates that these NI have different shapes, numbers and sizes. Lamin AC IHC staining (right image, [Fig 1A](#pone.0226199.g001){ref-type="fig"}) reveals the complete closure of the inclusion by the nuclear membrane with no contact to the cytoplasm.

10.1371/journal.pone.0226199.t002

###### Number of NI and cases with *BRAF*^*V600E*^ in the thyroid carcinoma cohort.

![](pone.0226199.t002){#pone.0226199.t002g}

  Tumor type                 Mean NI number / mm^2^ per case (range)   Number of cases with NI[\*](#t002fn002){ref-type="table-fn"} (%)   n valid cases   Number of cases with *BRAF*^*V600E*^   n valid cases
  -------------------------- ----------------------------------------- ------------------------------------------------------------------ --------------- -------------------------------------- ---------------
  ATC                        0.10 (0--1)                               1 (10.0%)                                                          10              0                                      10
  PDTC                       0.12 (0--1)                               2 (11.8%)                                                          17              0                                      19
  MTC                        0.30 (0--3)                               1 (10.0%)                                                          10              0                                      10
  FTC                        0.25 (0--3)                               2 (12.5%)                                                          16              0                                      16
  NIFTP                      0.11 (0--1)                               1 (11.1%)                                                          9               0                                      9
  PTC                                                                                                                                                                                            
  \- Solid variant           1.75 (0--6)                               2 (50.0%)                                                          4               0                                      4
  \- Tall cell variant       14.79 (0--53)                             13 (92.9%)                                                         14              8                                      17
  \- Follicular variant      0.88 (0--7)                               1 (12.5%)                                                          8               0                                      9
  \- Conventional variant    22.11 (0--114)                            4 (44.4%)                                                          9               6                                      11
  \- Hobnail variant         2                                         1 (100.0%)                                                         1               0                                      1
  \- Columnar cell variant   22                                        1 (100.0%)                                                         1               0                                      1
  Total                      4.60 (0--114)                             29 (29.3%)                                                         99              14                                     107

*Abbreviations*: NI = intranuclear inclusions; n = number.

\* Number of valid cases with the presence of at least 1 intranuclear inclusion

![Intranuclear inclusions in thyroid carcinoma (TC).\
**(A)** Characterization of intranuclear inclusions (NI). Images show NI in representative cases of our TC cohort. HE-staining (left image) demonstrates that NI (arrows) are completely closed with no contact to the cytoplasm on this plane; positive lamin AC immunostaining (right image) of the limiting membrane of the inclusion (arrow) reveals its nuclear membrane origin. (**B**) Positive immunoreactivity for autophagy-associated proteins in NI. Immunohistochemistry (IHC) shows NI with varying degrees of immunoreactivity for p62, LC3B, ubiquitin, cathepsin B and cathepsin D; partially different staining intensity in the inclusions for the same protein was detected. Image p62 demonstrates both NI with strong and partially dot-like immunoreactivity (arrows) and NI with almost no immunoreactivity (arrowhead). Also for cathepsin B and ubiquitin inclusions with different degrees of immunostaining were detected. Additionally, punctate distribution of LC3B in the inclusions (arrow) was observed. Cathepsin B- and cathepsin D-IHC also display cytoplasmic staining (asterix). Arrows: NI with strong immunoreactivity; arrowheads: NI with weaker or lacking immunoreactivity; asterix: cytoplasmic immunoreactivity. Original magnifications: 1,000 X.](pone.0226199.g001){#pone.0226199.g001}

Detection of *BRAF*^*V600E*^ mutation {#sec019}
-------------------------------------

Analysis of the thyroid cohort by NGS revealed that 14 of 107 cases (13%) harbored the *BRAF*^*V600E*^ mutation, whereby it was exclusively present in 14/43 (32%) PTCs. We identified the *BRAF* mutation mainly in the PTC tall cell variant with 8 of 14 (57%) and in the conventional PTC with 6 of 14 (42%), regarding the number of BRAF-mutated cases. In *NRAS* the Q61R mutation was found in 3/107 (2.8%) ATCs and 2/107 (1.9%) PDTCs. We detected with a maximum of 3/107 (2.8%) cases a rather low incidence of mutations in the genes of the Wnt pathway and we did not find any associations between these mutations and the occurrence of NI. More detailed information is provided in [Table 2](#pone.0226199.t002){ref-type="table"} and [S6 Table](#pone.0226199.s007){ref-type="supplementary-material"}. All mutations found in Cosmic with the prevalence of minimum 5% are listed; mutations listed additionally in the Clinvar database are marked.

Increased occurrence of lamin AC stained NI in PTC {#sec020}
--------------------------------------------------

Lamin AC positive inclusions occur most frequently (22/29; 76%) in PTCs; in the PTC tall cell variant 13 of 14 cases have at least one membrane-bounded inclusion ([Table 2](#pone.0226199.t002){ref-type="table"}). In contrast, we hardly detected any NI in ATC and PDTC. This is in line with the literature documenting that NI are mostly present in PTC \[[@pone.0226199.ref021], [@pone.0226199.ref022]\].

Accumulation of autophagy associated proteins in the NI {#sec021}
-------------------------------------------------------

Analysis of the NI by immunohistochemistry demonstrated positive immunoreactivity for the autophagy-associated proteins LC3B, ubiquitin, cathepsin D, p62 and cathepsin B in 14--29% of the cases ([Fig 1B](#pone.0226199.g001){ref-type="fig"} and [Table 3](#pone.0226199.t003){ref-type="table"}) with dot-like LC3B staining in the inclusions ([Fig 1B](#pone.0226199.g001){ref-type="fig"}) i.e. endogenous LC3B indicating the induction of autophagy \[[@pone.0226199.ref023]\]. Data for immunostaining was available in 96--100 of 107 cases due to lack of suitable materials in the other cases. We detected in 29/99 (29.3%) of the cases at least one membrane-bounded intranuclear inclusion with positive p62 immunostaining. Further in 20/98 (20.4%) of the thyroid carcinomas at least one membrane-bounded inclusion with positive immunoreactivity for ubiquitin was shown ([Fig 1B](#pone.0226199.g001){ref-type="fig"} and [Table 3](#pone.0226199.t003){ref-type="table"}); more details are listed in [Table 3](#pone.0226199.t003){ref-type="table"}.

10.1371/journal.pone.0226199.t003

###### Immunostaining of autophagy-related proteins in the intranuclear inclusions of the complete TC cohort.
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  Antibody      Thyroid carcinomas
  ------------- --------------------
  Cathepsin D   14 / 96 (14.6%)
  LC3B          20 / 100 (20.0%)
  Ubiquitin     20 / 98 (20.4%)
  Cathepsin B   20 / 97 (20.6%)
  p62           29 / 99 (29.3%)

The number of cases containing at least one intranuclear inclusion with positive immunoreactivity is shown; n = number

Degenerative material accumulates in the NI with no connection to the cytoplasm {#sec022}
-------------------------------------------------------------------------------

We performed TEM to study the NI in thyroid carcinomas in more detail. These inclusions are filled with degenerative materials such as remnants of mitochondria, endoplasmic reticulum, lamellar bodies and heterolysosomes ([Fig 2Aii, 2Bi, 2C and 2Di](#pone.0226199.g002){ref-type="fig"}). The absence of such degenerative changes in the cytoplasm indicates that these degradation processes take place completely delimited in the inclusions with no connection to the cytoplasm. Further, the content of the inclusions appears to be more condensed than cytoplasm ([Fig 2A--2D](#pone.0226199.g002){ref-type="fig"}). In fact even different stages of degradation of included material can be observed in electron microscopy, which resemble those of heterolysosomes when becoming residual bodies ([Fig 2C](#pone.0226199.g002){ref-type="fig"}). The inclusions are lined by the two membranes of the nuclear envelope with attached heterochromatin (h in [Fig 2Ai, 2Aii and 2Di](#pone.0226199.g002){ref-type="fig"}); along the inner membrane of the inclusion few ribosomes can be detected like the outer membrane of the nuclear envelope ([Fig 2Aii](#pone.0226199.g002){ref-type="fig"}). We observed nuclei with unusual invaginations ([Fig 2A](#pone.0226199.g002){ref-type="fig"}) and invaginations of surrounding cytoplasm into the nucleus ([Fig 2D and 2Di](#pone.0226199.g002){ref-type="fig"}). Thus, we suggest that some of these NI are formed by invaginations of the nuclear membrane.

![Ultrastructural analysis of intranuclear inclusions in papillary thyroid carcinomas with transmissionelectron microscopy (TEM).\
The image shows a nucleus with unusual invaginations (arrow) and another one with an additional intranuclear inclusion. (white arrow) (**A**). Increased magnification depicts the closure of the intranuclear inclusion with no contact to cytoplasm (Cy) (arrow) in the plane shown. This inclusion is lined by the two (inner and outer) nuclear membranes with attached membrane-associated heterochromatin (h) bordering a perinuclear space of regular width. There is no obvious difference to the situation at the nuclear membrane, which surrounds the entire nucleus (**Ai**). At both locations few ribosomes (arrowhead) are attached to the outer nuclear membrane whereas a nuclear lamina (white arrows) is adjacent to the inner membrane. The detail shows a heterolysosome (H), degenerating mitochondria (M) with already disintegrated cristae and remnants of endoplasmic reticulum (white arrowhead) (**Aii**). Image **B** depicts a nucleus with an extraordinarily large inclusion, which is shown enlarged on the right (**Bi**). This inclusion contains an accumulation of heterolysosomes (white arrows), lamellar bodies (arrows) and punctual accumulations of fine granular moderate electron-dense material (arrowhead) in a fine matrix of low electron density rich in membranes (**Bi**). The next image (**C**) indicates degradation of material in NI. While the right intranuclear inclusion (1) shows a clear and well preserved bordering nuclear membrane, condensation digestion and accumulation of already degraded material can be seen in 2, which is also surrounded by a membrane. However, the latter entirely lacks attached heterochromatin and pores. Morphology of 3 resembles a residual body and in our eyes represents the final stage of degradation with extremely condensed material inside an inclusion, as if it could become ejected soon. Image **D** demonstrates a nucleus with very deep but thin invaginations of surrounding cytoplasm (**D**) and an inclusion containing condensed more electron-dense material (arrow). The inclusion is lined by the double membrane of the nuclear envelope (**Di**).](pone.0226199.g002){#pone.0226199.g002}

Inclusions are located completely in the nucleus and laminated by lamin AC {#sec023}
--------------------------------------------------------------------------

To investigate the shape of the NI and to clarify if they are merely nuclear membrane invaginations with persistent cytoplasmic contact or \"real\" inclusions, we performed 3D nuclear imaging with lamin AC immunofluorescence. 3D-reconstructions were performed for tumor cell nuclei of two thyroid patients. Two representative reconstructed NI are shown in [Fig 3](#pone.0226199.g003){ref-type="fig"}. Here we prove that there is no connection between the content of the NI and the cytoplasm in the studied section planes ([Fig 3](#pone.0226199.g003){ref-type="fig"}). Since the limiting membrane of the inclusions was lamin AC positive, it is most probable that it originates from the nuclear membrane. These results demonstrate that membrane-bounded NI are \"real\", exclusively intranuclear compartments completely separated from the cytoplasm ([Fig 3](#pone.0226199.g003){ref-type="fig"}).

![3D nuclear imaging with lamin AC immunofluorescence in X-, Y- and Z-axis.\
For the first intranuclear inclusion 197 optical sections of 0.1μm were imaged and 137 of them were used for 3D reconstruction. The second intranuclear inclusion was reconstructed from 124 of 191 optical sections (0.1μm). Images reveal two representative tumor cell nuclei of a thyroid carcinoma patient. Both the nuclear membrane and the limiting membrane of the inclusion show lamin AC immunoreactivity (green staining), however that of the second inclusion is weaker. DNA staining was performed with DAPI (blue), which is lacking within the NI. The images demonstrate NI that are in all three planes completely closed and delimited by the nuclear membrane.](pone.0226199.g003){#pone.0226199.g003}

Correlation of ubiquitin with p62, LC3B, cathepsin B and cathepsin D {#sec024}
--------------------------------------------------------------------

We used chi-square cross table analysis to study associations between p62, ubiquitin, LC3B, cathepsin B and cathepsin D immunostaining reactivity in the NI ([Table 4](#pone.0226199.t004){ref-type="table"}). Samples were classified as positive (1) if at least one membrane-bounded inclusion showed positive immunoreactivity; cases lacking stained inclusions were classified as negative (0). Regarding the whole cohort, examination of 20 cases with positive ubiquitin immunostaining demonstrated that 19 of them also had NI with positive p62 immunostaining (p≤0.001) and 16 showed LC3B immunoreactivity (p≤0.001). We detected a significant relationship between ubiquitin and cathepsin B and cathepsin D immunoexpression in the NI (p≤0.001). Further, 18 of the 20 cases with LC3B- stained NI were also positive for p62 (p≤0.001) and 13 of the 14 cases with positive cathepsin D immunostaining in the membrane-bounded NI revealed an additional immunoreactivity for cathepsin B (p≤0.001). Similar results for the PTC cases are detailed in [Table 4](#pone.0226199.t004){ref-type="table"}.

10.1371/journal.pone.0226199.t004

###### Associations between p62, ubiquitin, LC3B, cathepsin B and cathepsin D immunoreactivity in intranuclear inclusions.
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  Cross Tabs    Whole TC cohort   PTC cases                         
  ------------- ----------------- ----------- ---------- ---------- ----------
  Ubiquitin     p62               19 / 97     \< 0.001   17 / 37    \< 0.001
  LC3B          16 / 98           \< 0.001    15 / 37    \< 0.001   
  Cathepsin B   16 / 97           \< 0.001    15 / 36    \< 0.001   
  Cathepsin D   14 / 95           \< 0.001    14 / 36    \< 0.001   
  p62           LC3B              18 / 99     \< 0.001   15 / 37    0.001
  Cathepsin B   Cathepsin D       13 / 95     \< 0.001   13 / 36    \< 0.001

n = number of thyroid carcinomas with positive intranuclear inclusions/valid cases. P values were calculated using two-sided Fisher's exact test.

Autophagy-associated proteins are co-localized in the inclusions {#sec025}
----------------------------------------------------------------

To verify if these autophagy-associated proteins are located within the same inclusion, double-immunofluorescence labelled serial sections were analyzed by STED microscopy. [Fig 4](#pone.0226199.g004){ref-type="fig"} shows three DAPI-stained nuclei with NI. Co-localization of ubiquitin/LC3B ([Fig 4A](#pone.0226199.g004){ref-type="fig"}), ubiquitin/p62 ([Fig 4B](#pone.0226199.g004){ref-type="fig"}) and LC3B/p62 ([Fig 4C](#pone.0226199.g004){ref-type="fig"}) is demonstrated in the same inclusion by the merged color yellow ([Fig 4](#pone.0226199.g004){ref-type="fig"}, arrows).

![Double-IF studies of autophagy-associated proteins in PTC sections.\
**(A)** LC3B/ubiquitin double-IF labeling. DAPI staining (blue) reveals a nucleus with an intranuclear inclusion containing LC3B (red) and ubiquitin (green) immunostaining. The superimposition of both signals results in yellow color (arrows, merged image) proving a co-localization of the two proteins. **(B)** p62/ubiquitin double-IF labeling. An intranuclear inclusion with tense accumulation of p62 (red staining) and ubiquitin (green staining) is seen; yellow staining (arrow) in the merged image indicates p62/ubiquitin co-localization. **(C)** LC3B/p62 double-IF labeling. The images show strong LC3B (red staining) and p62 (green staining) immunoreactivity in the inclusion. There is strong LC3B/p62 co-localization displayed by the intense yellow color in the merged image (arrows).](pone.0226199.g004){#pone.0226199.g004}

Accumulation of mutant BRAF protein within the NI {#sec026}
-------------------------------------------------

We analyzed the FFPE thyroid carcinomas on mutant BRAF by IHC and confirmed our results of the NGS analysis (see above). Briefly, the same 14 of 107 cases, which were formerly proven to harbor the *BRAF*^*V600E*^ mutation, showed positive immunostaining for anti-B-Raf antibody, detecting exclusively BRAF^V600E^. In 8 of 14 cases immunoreactivity for mutant BRAF was only seen in the cytoplasm but not in the inclusions. Intriguingly, the other 6 cases revealed, additional to cytoplasmic staining, positive BRAF^V600E^ staining within the NI showing an accumulation of BRAF^V600E^ protein in 0--28% of the inclusions. ([Fig 5A](#pone.0226199.g005){ref-type="fig"}).

![Study of mutant BRAF protein found within the inclusions.\
**(A)** BRAF^V600E^-IHC analysis of PTC sections depicts additional to cytoplasmic immunopositivity (asterix) an accumulation of BRAF^V600E^ within the intranuclear inclusions (NI). The left image display NI with varying degrees of immunoreactivity for BRAF^V600E^ with very strong immunostaining within the NI (arrows) and weaker staining (arrowheads). The right image demonstrates NI containing an accumulation of BRAF^V600E^ (arrows) and NI with almost no immunoreactivity for mutant BRAF (arrowheads). Original magnifications: 1,000 X. **(B-D)** Double-IF studies demonstrate co-localization of BRAF^V600E^ with autophagy-associated proteins in NI of PTC sections. Nuclei were stained with DAPI (blue) to detect NI. **(B)** BRAF^V600E^/LC3B double-IF labeling. The images reveal the same NI with immunopositivity for BRAF^V600E^ (red staining) and for LC3B (green staining). The merged image shows the superimposition of the signals for BRAF^V600E^ and LC3B with formation of yellow color (arrow) indicating BRAF^V600E^/LC3B co-localization. **(C)** BRAF^V600E^/p62 double-IF labeling. An NI with accumulation of BRAF^V600E^ (red staining) and p62 (green staining) is shown; BRAF^V600E^/p62 is demonstrated by intense yellow color (arrows) in the merged image. **(D)** BRAF^V600E^/ubiquitin double-IF labeling. A nucleus with a large inclusion is shown with positive immunoreactivity for both mutant BRAF (red staining) and ubiquitin (green staining); the merged color yellow (arrow) points out the co-localisation of BRAF^V600E^ and ubiquitin in the same inclusion.](pone.0226199.g005){#pone.0226199.g005}

Co-localization of mutant BRAF with p62, LC3B and ubiquitin in the NI {#sec027}
---------------------------------------------------------------------

To investigate if the accumulation of mutant BRAF protein is associated with autophagy and with proteolytic processes, we performed double-IF studies. STED microscopy images demonstrated three nuclei with accumulations of mutant BRAF within the inclusions ([Fig 5B--5D](#pone.0226199.g005){ref-type="fig"}). We detected co-localization of BRAF^V600E^ with LC3B ([Fig 5B](#pone.0226199.g005){ref-type="fig"}), with p62 ([Fig 5C](#pone.0226199.g005){ref-type="fig"}) and with ubiquitin ([Fig 5D](#pone.0226199.g005){ref-type="fig"}) respectively in the same inclusion. The formation of the merged color yellow proves the co-localization ([Fig 5](#pone.0226199.g005){ref-type="fig"}, arrows). Additionally we searched for a possible co-localization of mutant BRAF with autophagy-associated proteins in the cytoplasm. Double-IF studies showed few co-localizations of BRAF^V600E^ with ubiquitin and with LC3B but not with p62 after detailed z-stacks analysis; ubiquitin and LC3B immunostainings in the inclusions were much more intense than in the cytoplasm ([S1 Fig](#pone.0226199.s001){ref-type="supplementary-material"}).

Increased occurrence of NI in PTC cases harboring *BRAF*^*V600E*^ mutation {#sec028}
--------------------------------------------------------------------------

As we detected *BRAF*^*V600E*^ mutation only in the PTC cases of our cohort, we asked whether *BRAF*^*V600E*^ mutation is somehow associated with NI. Mann--Whitney U-test showed a significant positive correlation between lamin AC stained NI and *BRAF* mutational status in PTC. Our results reveal that the number of NI is significantly higher in PTC cases harboring *BRAF*^*V600E*^ mutation versus PTC cases with wild-type BRAF (p = 0.042; [Fig 6A](#pone.0226199.g006){ref-type="fig"}).

![Associations between *BRAF* mutational status and NI in PTCs.\
**(A)** The diagram depicts a significant association between *BRAF* mutational status and the number of NI/case with p = 0.042. **(B-F)** Significant correlation between *BRAF* mutational status and immunoreactivity for autophagy-associated proteins in NI is shown. **(B)** p62 positive NI/case vs. *BRAF*^*V600E*^: p = 0.024, **(C)** LC3B positive NI/case vs. *BRAF*^*V600E*^: p = 0.003, **(D)** Ubiquitin positive NI/case vs. *BRAF*^*V600E*^: p = 0.032, **(E)** Cathepsin B positive NI/case vs. *BRAF*^*V600E*^: p = 0.035 and **(F)** Cathepsin D positive NI/case vs. *BRAF*^*V600E*^: p = 0.013. Results are significant at \*p≤0.05, \*\*p≤0.01, and \*\*\*p≤0.001.](pone.0226199.g006){#pone.0226199.g006}

Correlation between p62, ubiquitin, LC3B, cathepsin B, cathepsin D expression and *BRAF* mutational status {#sec029}
----------------------------------------------------------------------------------------------------------

One aim of this study was to investigate the reason of the occurrence of NI. As these inclusions mainly occurred in PTC cases, we focused on this tumor entity. We detected by Mann--Whitney U-test a significant correlation between immunoreactivity for autophagy-associated proteins in the inclusions and *BRAF* mutational status. Briefly, the number of NI with positive immunostaining for p62, ubiquitin, LC3B, cathepsin B and cathepsin D were significantly higher (p≤0.035) in PTC cases harboring *BRAF*^*V600E*^ mutation versus PTC tumors with *BRAF* wild-type ([Fig 6B--6F](#pone.0226199.g006){ref-type="fig"}).

Discussion {#sec030}
==========

Intranuclear inclusions have been described both in normal and neoplastic tissues \[[@pone.0226199.ref001]--[@pone.0226199.ref007], [@pone.0226199.ref024]\]. The presence of NI is generally regarded as an unspecific morphologic feature. Nevertheless, they are used as a diagnostic feature in several tumors such as melanomas and meningiomas and as a prognostic factor in clear cell renal cell carcinoma \[[@pone.0226199.ref010]\]. Also, they have a diagnostic significance in thyroid cancer \[[@pone.0226199.ref004], [@pone.0226199.ref005], [@pone.0226199.ref012]\]. Therefore, we investigated NI in thyroid cancer in more detail to clarify whether they also have a potential biological function.

NI are known to represent invaginations of the cytoplasm into the nucleus \[[@pone.0226199.ref010]\]. In thyroid carcinoma nuclear membrane-bounded inclusions of different size and shape are found \[[@pone.0226199.ref010]\]. Occasionally, artificially formed so-called "bubbles" without limiting nuclear membrane-resembling inclusions are observed \[[@pone.0226199.ref011]\]. This is in line with our results. Asioli et al used emerin staining for the detection of inclusions to exclude artificial bubbles \[[@pone.0226199.ref011]\]. In our present study, we have established diagnostic criteria for true NI. First, we have only considered an inclusion as positive if this inclusion was limited by a lamin AC (nuclear membrane marker) stained intact membrane proving that these inclusions are not artificial bubbles but real inclusions. Second, the NI should be completely closed in the plane seen through the microscope. Arora et al stated that the finding of inclusions of different shape and size in sections of the same tumor indicates a continuous process producing the inclusions \[[@pone.0226199.ref010]\]. Thus, we suppose there may be several stages of inclusion formation seen through the microscope. As we are interested in the stage when the invagination is completely closed we focused only on those inclusions, which were completely closed. Since the light microscope provides an image only in two dimensions we additionally performed 3D reconstructions of some nuclei.

Ultrastructural studies have shown that the inclusions in thyroid carcinoma cells are formed by the nuclear envelope \[[@pone.0226199.ref005], [@pone.0226199.ref012], [@pone.0226199.ref013]\]. We confirmed this, supported by our transmission electron microscope (TEM) images showing nuclei with NI and invaginations and both are limited by a nuclear membrane. We further investigated this topic and demonstrated by 3D reconstruction ([Fig 3](#pone.0226199.g003){ref-type="fig"}) that these NI were completely surrounded by the nuclear membrane and closed. Papotti et al also studied PTC nuclei but they reported that the inclusions are always connected to the cell cytoplasm \[[@pone.0226199.ref025]\]. This is in contrast to our results as our 3D reconstructions prove that the inclusions were completely located within the nucleus lacking any contact to the cytoplasm. It is very likely that these inclusions develop by invagination of the cytoplasm into the nucleus followed by later closure of the invagination. We suppose that the 3D reconstruction shown in Papotti et al reflects an early stage of a cytoplasmic invagination in the process of NI formation. However, nobody can exclude that some invaginations may not close and stay connected to the cytoplasm for a longer time.

TEM studies of Oyama et al showed that NI in thyroid carcinoma cells contain cell organelles, fragments of mitochondria and heterolysosomes \[[@pone.0226199.ref005]\], which is also in line with our TEM results ([Fig 2](#pone.0226199.g002){ref-type="fig"}). As they observed autophagosomes with crumpled membranes showing degradation in the inclusions, they discussed the possibility that these inclusions may be true inclusions and are not connected by the surrounding cytoplasm to explain the storage of products in the inclusions.

We investigated this observation in more detail and showed autophagy-associated proteins p62, ubiquitin and LC3B almost exclusively located in the NI with an accumulation of these proteins there but only weak cytoplasmic staining ([Fig 1B](#pone.0226199.g001){ref-type="fig"}) indicating it is not merely a passive invagination process. Our studies of inclusions using immunohistochemistry ([Fig 1B](#pone.0226199.g001){ref-type="fig"}), electron microscopy ([Fig 2](#pone.0226199.g002){ref-type="fig"}), and 3D reconstruction ([Fig 3](#pone.0226199.g003){ref-type="fig"}) showed that these inclusions are completely closed on the 2D and 3D plane. The content of these inclusions is more condensed and contains progressively degenerated cell organelles when compared to the organelles in the cytoplasm which supports again that a completely enclosed NI has no continuity into to the cytoplasm ([Fig 2](#pone.0226199.g002){ref-type="fig"}). NI with highly degenerative cytoplasmic components were already observed in the mid and late 1950s \[[@pone.0226199.ref006], [@pone.0226199.ref026]\]; they assumed that complete separation of the inclusions from the cytoplasm could induce a faster degeneration process within the inclusions. In an earlier study \[[@pone.0226199.ref027]\] we detected that the lack of survivin in hepatocytes causes lack of chromosomal passenger complex proteins at the centromeres during mitosis, but reappeared in NI in interphase nuclei. The reason why these proteins are detected in NI is unclear, but it can be assumed that they could be degraded in the inclusions. Recently, we showed that NI in HCC contained autophagy-associated proteins \[[@pone.0226199.ref008]\]. In the current study we provide evidence that cathepsin B and cathepsin D ([Fig 1B](#pone.0226199.g001){ref-type="fig"}) are present inside NI. These proteases are usually restricted to lysosomes. In this context, we assume that they digest the content of the inclusions and thus promote the degeneration of the organelles \[[@pone.0226199.ref008]\]. The possibility of protein digestion in NI of meningiomas \[[@pone.0226199.ref009]\] and in nuclei with spherical eosinophilic inclusions \[[@pone.0226199.ref028]\] has already been discussed.

We were able to find p62 positive inclusions in 29.3%, ubiquitin in 20.4%, LC3B in 20%, cathepsin B in 20.6% and cathepsin D in 14.6% of all NI and a positive association of them to each other. We demonstrate by immunofluorescence double-staining that p62/ubiquitin, LC3B/p62 and ubiquitin/LC3B are co-localized in NI. This is consistent with other studies pointing out autophagy-associated proteins \[[@pone.0226199.ref008], [@pone.0226199.ref029]\] and autophagy activities \[[@pone.0226199.ref030], [@pone.0226199.ref031]\] in the nucleus. Intriguingly, our TEM results suggest different stages of degradation of included material in NI ([Fig 2C](#pone.0226199.g002){ref-type="fig"}). Nevertheless, additional functional experiments are necessary to confirm the hypothesis of autophagy in the NI.

We observed that the NI were mostly present in the PTCs and were nearly absent in other thyroid cancer entities, which is in line with the literature as they are a diagnostic criteria for PTC \[[@pone.0226199.ref021], [@pone.0226199.ref022]\]. For example, no NI were detected in the 3 ATC and 2 PDTC cases, harboring NRAS Q61R mutation. The presence of *BRAF*^*V600E*^ mutation in 32% of PTCs confirms the literature, although our result is in the lower range, as it is reported that the *BRAF*^*V600E*^ mutation occurs in about 45% (30 to 70%) of PTCs \[[@pone.0226199.ref032]--[@pone.0226199.ref036]\]. The occurrence of *BRAF*^*V600E*^ mutation depends, among others, on the region, where the study is conducted and the available diet there \[[@pone.0226199.ref037]\]; Guan et al demonstrated the association of high iodine intake with *BRAF*^*V600E*^ mutation \[[@pone.0226199.ref038]\]. Our study group consisted of patients from the European region, who do not consume iodine-rich seafood so often. In addition, the prevalence of *BRAF*^*V600E*^ mutation is also depended on the studied variant of PTC. In our cohort were also 9 follicular variant PTCs and 4 solid variant PTCs, whereby PTC solid variant rarely harbors *BRAF*^*V600E*^ mutation \[[@pone.0226199.ref039]\] and the *BRAF*^*V600E*^ mutation rate is in PTC follicular variant with 12--40% lower than in PTC conventional and PTC tall cell variant \[[@pone.0226199.ref032], [@pone.0226199.ref040], [@pone.0226199.ref041]\]. In our current study, we found out that the number of NI was significantly higher in PTCs harboring a *BRAF*^*V600E*^ mutation. This is in line with other studies on thyroid carcinomas \[[@pone.0226199.ref042]--[@pone.0226199.ref045]\]. They observed a positive correlation between *BRAF*^*V600E*^ mutation and nuclear features of PTC (including NI) and tumor cells first defined by Finkelstein et al as "plumb eosinophilic cells" also showing inclusions. However, these studies focused on a general association between *BRAF*^*V600E*^ mutation and the classic nuclear features of PTC and did not investigate explicitly membrane-limited NI, as we did. The NI we observed were morphologically similar to the "plump cells" described above, with the height of tumor cells less than twice the width and mostly eosinophilic \[[@pone.0226199.ref045]\].

Further, we asked whether *BRAF*^*V600E*^ mutation plays a role in the formation of inclusions. It is documented that in human melanoma cells *BRAF*^*V600E*^ induces spindle abnormalities, excess centrosomes and misaggregation of chromosomes leading to aneuploidy \[[@pone.0226199.ref046]\] due to phosphorylation of MPS1 by BRAF^V600E^ \[[@pone.0226199.ref047]\]. Fischer et al \[[@pone.0226199.ref048]\] reviewed the reasons for alterations in the nuclear envelope (NE) in human cancers. They reported that inter alia chromosomal instability and aneuploidy can lead to alterations in the NE such as cell-to-cell variation in NE size and shape and to deep infoldings. Further, Fischer et al showed that *RET/PTC1* microinjection in normal human thyroid epithelial cells induced NE irregularity during the interphase and the forming of inclusions \[[@pone.0226199.ref049], [@pone.0226199.ref050]\]; they concluded that *BRAF* mutations may directly lead to inclusions by altering NE and chromatin organization \[[@pone.0226199.ref048]\]. This is supported by a study showing that targeted expression of BRAF^V600E^ in thyroid cells of transgenic mice resulted in irregularity of nuclear contours and occasional nuclear groves \[[@pone.0226199.ref051], [@pone.0226199.ref052]\]. The mechanisms involved in the formation of inclusions are, despite of several studies \[[@pone.0226199.ref053]--[@pone.0226199.ref055]\], still quite unknown. We suppose that different factors may induce the formation of inclusions and that the *BRAF*^*V600E*^ mutation is one of them.

Intriguingly, BRAF^V600E^ protein staining was also positive in NI. The localization of the BRAF^V600E^ antibody (VE1) in the nucleus, cytoplasm and cell membrane is documented (<https://www.uniprot.org/uniprot/P15056>). We scored the inclusions as positively stained only with simultaneous cytoplasmic staining and confirmation of the *BRAF*^*V600E*^ mutation by genetic analysis to exclude artificially incorrect results. We demonstrate the co-localization of BRAF^V600E^/ubiquitin, BRAF^V600E^/LC3B and BRAF^V600E^/p62 in the NI by double-immunofluorescence. To our knowledge, this is the first study showing the presence of mutant BRAF simultaneous with autophagy-associated proteins in NI. Studies investigating the degradation of mutant BRAF revealed that BRAF^V600E^ requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors by ubiquitin-dependent degradation in the proteasome \[[@pone.0226199.ref056]\]. Further, as shown in thyroid cancer cells harboring *BRAF*^*V600E*^ mutation, the binding of the co-chaperone BAG3 to BRAF protected it from degradation by inhibiting HSP70-mediated delivery to the proteasome \[[@pone.0226199.ref057], [@pone.0226199.ref058]\]. Samant et al revealed that the E3 ubiquitin ligase CUL5 is involved in the Hsp90-inhibitor-induced BRAF^V600E^ degradation and NEDD8 conjugation of CUL5 is required for later degradation \[[@pone.0226199.ref059]\]. Recently, it was reported that the deubiquitinating enzyme USP28 stabilizes the F-box WD repeat-containing protein 7 (FBW7) and this results in SKP1/CUL1/F-box (SCF) mediated proteasomal degradation of BRAF^V600E^ \[[@pone.0226199.ref060], [@pone.0226199.ref061]\]. In the present study, we considered whether co-localization of mutant BRAF with autophagy-associated proteins is a passive process due to passive invagination of the cytoplasm into the inclusion, or rather an active proteolytic process. Although we also found few co-localizations of mutant BRAF with ubiquitin and LC3B (very weak staining) in the cytoplasm, a possible co-localization with p62 was lacking ([S1 Fig](#pone.0226199.s001){ref-type="supplementary-material"}). The immunoreactivity for ubiquitin and LC3B within the inclusions was much more pronounced than in the cytoplasm, with an accumulation of these proteins in NI ([S1 Fig](#pone.0226199.s001){ref-type="supplementary-material"}), which indicates an active proteolytic process. Thus, our results suggest that at least a part of the BRAF^V600E^ protein is degraded inside NI possibly through ubiquitin-dependent lysosomal degradation.

We found that *BRAF*^*V600E*^ positivity was first associated with an increase in number of inclusions and second with immunoreactivity for autophagy-associated proteins in the inclusions. The induction of autophagy in melanomas by hyperactivation of oncogenic BRAF is documented \[[@pone.0226199.ref018]\]. In papillary thyroid carcinoma *BRAF*-activated long non-coding RNA contributed to cell proliferation and activated autophagy \[[@pone.0226199.ref019]\]. Kim et al also reported the association of *BRAF*^*V600E*^ mutation with higher levels of autophagy-related proteins in PTC \[[@pone.0226199.ref062]\].

In summary, this study shows the existence of NI in thyroid carcinoma, which are completely surrounded by nuclear membrane with no contact to the cytoplasm. Therefore we would not term these inclusions "pseudoinclusions" but rather "real inclusions" or "true inclusions". How these true inclusions are formed is unknown but they may develop by closure of cytoplasmic invaginations. The presence of autophagy-associated proteins within the inclusions together with degenerated organelles and lysosomal proteases like cathepsins suggest that these inclusions play a role in autophagy and proteolysis. We demonstrate that the number of these true inclusions is positively associated with the *BRAF*^*V600E*^ mutation and show that mutant BRAF is detectable within these inclusions.

Double-immunofluorescence revealed mutant BRAF is co-localized with p62, LC3B and ubiquitin, respectively, which may imply that mutant BRAF is exposed to a proteolytic process.

Our results suggest that NI are not only of diagnostic importance in thyroid cancer, but above all may have a potential biological function.

Supporting information {#sec031}
======================

###### Double-IF studies of BRAF^V600E^ protein in PTC sections.

(A-B) BRAF^V600E^/ubiquitin double IF labelling (A) The image demonstrates co-localization of mutant BRAF (red) with ubiquitin (green) within the inclusions (arrow) proved by the merged color yellow with lack of co-localization in the cytoplasm (B) Another nucleus with inclusions containing an accumulation of ubiquitin is seen with co-localization of BRAFV600E/ubiquitin both within the intranuclear inclusion (NI) and in the cytoplasm (arrows). Both the merged color yellow and the immunoreactivity for ubiquitin are stronger in the NI than in the cytoplasm; only weak distribution of ubiquitin is seen in the cytoplasm. (C-D) After z-stack analysis of the same nucleus BRAF^V600E^/LC3B co-localizations were found on two different z-planes (C) Co-localization of BRAF^V600E^ (red) with LC3B (green) in the NI (arrow) but not in the cytoplasm is shown in this single z-plane image. (D) Few co-localizations of mutant BRAF with LC3B are seen in the cytoplasm (arrows) with no co-localization within the same NI on the other z-plane. Immunostaining for LC3B was stronger in the NI than in the cytoplasm demonstrating an accumulation of LC3B within the NI. (E-F) BRAF^V600E^/p62 double IF labelling reveals co-localization of BRAF^V600E^ (red) with p62 (green) in two inclusions proven by the merged color yellow (arrows) with lack of co-localization in the cytoplasm.

(TIF)

###### 

Click here for additional data file.

###### Immunohistochemistry antibodies and staining protocols.

(PDF)

###### 

Click here for additional data file.

###### NGS study: Panel of analyzed genes and exons.

(PDF)

###### 

Click here for additional data file.

###### 3D-Imaging of the inclusions: Antibodies used for double-immunofluorescence and staining conditions.

(PDF)

###### 

Click here for additional data file.

###### Double-labeling immunofluorescence microscopy: LC3B/ubiquitin, p62/ ubiquitin and LC3B/p62.

(PDF)

###### 

Click here for additional data file.

###### Double-labeling immunofluorescence microscopy: BRAF^V600E^/LC3B, BRAF^V600E^/p62 and BRAF^V600E^/ubiquitin.

(PDF)

###### 

Click here for additional data file.

###### NGS study: Mutations in the analyzed genes of the thyroid carcinoma cohort.

(PDF)

###### 

Click here for additional data file.
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Reviewer \#1: I commend the authors of the study for their findings. Their correlation of autophagy genes

I think the authors samples maybe slightly skewed however and they may need to address the prevalence of BRAF in the literature that occurs in classical, poorly differentiated and FVTC. Rates in most studies of BRAF positive at in the 60-70% range. Can the authors explain their sample selection and why they were unable to see BRAF mutations in these other subgroups. There is a need to increase your sample size to explain the rational for not observing these changes as it would mean the clinical sample size is too low.

I note the authors correlate the autophagy genes in patients with the BRAF mutation. There are 14 patients with the BRAF mutation and a significantly higher number of tumor samples with at least upregulation of one or more of the autophagy genes. Can the authors comment on the total cumulative number of patients with at least one of the autophagy genes unregulated. Can the authors also explain if the BRAF mutation is only present in 14% of patients and more than 29% of patients have a change in at least one autophagy gene the effect is only at best 50% of patients with changes in the autophagy genes. And what is different about these tumors and the tumor biology versus the patients without these features. Potentially a correlation with recurrence and disease free survival and outcomes would be important.

It would be also important to see the labeling of BRAF wt in the inclusions. I think the authors need to see if there is clustering of wt in nuclear inclusions.

Reviewer \#2: This manuscript has surprising, convincing, important new data on the structural features of intranuclear cytoplasmic inclusions: Intranuclear cytoplasmic inclusions are (at least in the carefully studied examples) completely bound by nuclear lamina and nuclear membranes.

There are minor editorial corrections/suggestions:

1\. Line 79 take out word \"briefly\".

2\. Line 204 Did you really homogenize the cells in 70% ethanol (more likely aquaeous)? Also, cells should not have needed permeabilization since they went through xylene.

3\. Line 318-19. The writing is not clear. I think you mean \"No other genes were mutated in more than one case\".

4\. Line 324. Not clear. I think you can delete the beginning of the sentence to say \"Lamin A/C positive inclusions occur most frequently\...\"

5\. Line 389-390. I don\'t think you have any basis to speculate about the temporal aspects of the fate of inclusions. I would say something like \"as if it could become ejected soon\"

6\. The authors may want to include this reference on intranuclear cytoplasmic inclusions:

Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A, Khan A.

2004\. beta-Catenin expression in thyroid follicular lesions: Potential role in

nuclear envelope changes in papillary carcinomas. Endocr Pathol 15:329--

337\.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Andrew H. Fischer

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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25 Oct 2019

Editor Comments: First of all, we want to thank you for taking the time to review our manuscript. We have highlighted the changes in our manuscript within the document by using coloured (blue) text; deleted text is marked in red and crossed out. The information regarding page numbers refers to the previous version of the manuscript. Journal Requirements (JR) and the responds of the author (AC) are listed below.

Journal Requirements:

JR.1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

AC.1. We have checked PLOS ONE\'s style requirements and we have incorporated corresponding author's initials in parentheses after the email address. Additionally, we have corrected the formatting of the headings.

JR.2. We noticed minor instances of text overlap with the following previous publication(s), which need to be addressed:

doi: 10.1002/cjp2.129

In your revision please ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

AC.2. Thank you for your comment regarding minor instances of text overlap with our own previous publication. We have checked this and found some parts mainly concerning background information and some idioms and we apologize for this. We rephrased or quoted any duplicated text outside the methods section in the revised manuscript.

Response to the Reviewer: First of all, we want to thank you for taking the time to review our manuscript. We have highlighted the changes in our manuscript within the document by using colored (blue) text; deleted text is marked in red and crossed out. The information regarding page numbers refers to the previous version of the manuscript. The comments of the reviewer (RC) and the responds of the author (AC) are listed below.

Response to Reviewer 1

RC: I think the authors samples maybe slightly skewed however and they may need to address the prevalence of BRAF in the literature that occurs in classical, poorly differentiated and FVTC. Rates in most studies of BRAF positive at in the 60-70% range. Can the authors explain their sample selection and why they were unable to see BRAF mutations in these other subgroups. There is a need to increase your sample size to explain the rational for not observing these changes as it would mean the clinical sample size is too low.

AC: Thank you for pointing out the prevalence of BRAF in the literature regarding the different entities. We incorporated additional references into the discussion section (line 612 of the previous manuscript) of the revised manuscript. It is documented that the occurrence of BRAF V600E mutation depends, among others, on the region, where the study is conducted and the available diet there \[1\]. Guan et al demonstrated the association of high iodine intake with BRAF V600E mutation \[2\]. The study cohort consisted of patients with classical PTC and revealed that in regions with high iodine contents in natural drinking water the prevalence of BRAF V600E mutation was significantly higher (69%) than in regions with normal iodine content (53%) \[2\]. A study of Jin et al revealed that 63.7% of the Chinese patients with PTC harbored the BRAF V600E mutation and they pointed out that high dietary iodine intake from rich sea foods may contribute to this high prevalence of BRAF V600E mutation; however they did not elaborate on the variants of studied PTCs. The prevalence of BRAF V600E mutation is also depended on the studied variant of PTC. It is documented that BRAF V600E mutation occurs significantly more frequently in the conventional variant of PTC than in the follicular variant with 58% versus 31% \[3\] and 75% versus 40% \[4\]. Only classical PTC cases were analyzed in the above mentioned study by Guan et al. with the detection of 53% BRAF V600E mutation in regions with normal iodine content. There are also studies reporting a lower prevalence of BRAF V600E mutation in about 45% (30 to 70%) of PTCs \[5--9\], with 12% of follicular variant PTC and 77% of tall cell variant PTC harboring this mutation \[5\]. In our study cohort 14 of 43 PTCs (32%) harbored the BRAF V600E mutation. The reason for this relatively low occurrence of the BRAF V600E mutation could be that first of all, our study group consisted of patients from the European region, who do not consume iodine-rich seafood so often. Secondly, in our study group were also 9 follicular variant PTCs, 1 hobnail variant PTC, 1 columnar cell variant PTC and 4 solid variant PTCs, whereby PTC solid variant rarely harbors BRAF V600E mutation \[10\] but more frequently BRAF VK600-1E mutation \[10, 11\] and BRAF V600delinsAL \[5, 10\]. Our study cohort consisted of 10 ATCs, 10 PDTCs and 9 FTCs, which were all BRAF V600E negative. It is documented that PDTCs and ATCs were more likely to have BRAF V600E mutation when they arise from papillary carcinoma \[9, 12, 13\]. The BRAF V600E mutation was found in about 5-20% \[14--16\] of PDTCs and in 11-45% of ATCs \[17--19\]. In the study of Landa et al, in which 45% of ATCs harbored the BRAF V600E mutation, they used NGS technique and adopted an ultra-deep sequencing strategy, enabling an average depth of coverage \[18, 20\]. In our current study, we used also NGS but we did not perform ultra-deep sequencing described by Landa et al. Another reason why we detected no BRAF mutation in our PDTC and ATC cases might be that they developed de novo rather than arised from papillary carcinomas \[9, 12\]. Nevertheless, our current study did not focus on the prevalence of BRAF V600E mutation in thyroid cancer. Our aim was to show that NI so often observed in daily microscopic observations, are completely surrounded by the nuclear membrane. In addition, we wanted to show that these inclusions, which have so far been considered of less important, might have a function because they contain accumulations of proteins associated with autophagy and proteolysis. Therefore, although we appreciate your comment, we believe that increasing the number of ATC and PDTC cases would not be useful, as the message regarding the characteristics of intranuclear inclusions remains the same.

RC: I note the authors correlate the autophagy genes in patients with the BRAF mutation. There are 14 patients with the BRAF mutation and a significantly higher number of tumor samples with at least upregulation of one or more of the autophagy genes. Can the authors comment on the total cumulative number of patients with at least one of the autophagy genes unregulated. Can the authors also explain if the BRAF mutation is only present in 14% of patients and more than 29% of patients have a change in at least one autophagy gene the effect is only at best 50% of patients with changes in the autophagy genes.

AC: We apologize that the manuscript was not clear at this point, which led to misunderstandings, as we did not investigate the expression of genes. We only found out that in 14-29% of all cases there was an accumulation of autophagy-associated proteins within the inclusions. Further, the number of NI, which showed immunopositivity for autophagy-associated proteins within the inclusions was higher in BRAF V600E positive cases than in cases with BRAF wild-type. We agree that about 50% of the cases harbored NI with an accumulation of autophagy-associated proteins within them although they have no BRAF mutation. But the number of such filled NI was lower in BRAF wild-type cases. In our opinion the BRAF V600E mutation is only one factor, which may regulate the accumulation of the autophagy-associated proteins within NI and the formation of NI (line 635-637 of the previous manuscript). Nevertheless, we assume that there are also other factors that play a role in these biological processes.

RC: And what is different about these tumors and the tumor biology versus the patients without these features. Potentially a correlation with recurrence and disease free survival and outcomes would be important.

AC: Unfortunately, we don't have survival data of the patients.

RC: It would be also important to see the labeling of BRAF wt in the inclusions. I think the authors need to see if there is clustering of wt in nuclear inclusions.

AC: Thank you for your suggestion. We provided the antibody anti-BRAF (\#NBP1-47668, Novus, Littleton, CO), which detects BRAF wild-type (<https://www.novusbio.com/PDFs/NBP1-47668.pdf>).

We performed IHC studies on whole FFPE tissue sections of two PTCs of our study group: one case harboring the BRAF V600E mutation and the other case BRAF wild-type, proven formerly by NGS. We detected in both cases NI with accumulations of BRAF wild-type protein and NI without immunoreactivity for BRAF wild-type regardless of BRAF mutation status (Additional figure for review is provided below). Further, we observed varying degrees of immunoreactivity for BRAF wild-type within the NI (arrows) whereby some NI showed relatively weaker immunostaining (arrows). We found BRAF wild-type immunopositivity also in the case in which formerly BRAF V600E mutation was proved by NGS. This result is unexpected and can have several reasons. One explanation may be heterogeneity in this case with both BRAF wild-type and BRAF V600E cells coexisting in the same tumor. Also other studies have observed the existence of BRAF heterogeneity in some tumors \[21, 22\]. Another explanation can be that the mutated BRAF protein also reacts to some degree with this antibody. We contacted Novus Biologicals, from which the antibody anti-BRAF (\#NBP1-47668) was purchased, and asked how specific this antibody is. The answer was that since this antibody is made from a full length recombinant, which is based on the wild type sequence, NP_004324 its possible that it may or may not pick up the mutated form. Additionally, they said that as long as the epitope of NBP1-47668 is not directly over the mutation in BRAF V600E then this antibody should pick up the wild-type and mutant form.

In our manuscript we documented the accumulation of mutant-BRAF protein within NI and now we also found BRAF wild-type protein within NI. It is documented that high BRAF expression was significantly correlated with poor patient survival in melanoma \[23, 24\]. As we also found clustering of BRAF wild-type in NI this might due to a biological mechanism to deal with excess BRAF protein.

Additional Figure for Review

Immunohistochemistry: BRAF Antibody (OTI5A9) \[NBP1-47668\]

The image is displayed in the attached Word document.

The images depict immunostaining of representative PTC cases harboring BRAF wild-type (A, B) and BRAF V600E mutation (C, D) proven by NGS; varying degrees of immunoreactivity for BRAF (\#NBP1-47668, Novus, Littleton, CO) is shown both in the intranuclear inclusions (arrows) and in the cytoplasm. Original magnifications: 1,000 X.

Response to the Reviewer: First of all, we want to thank you for taking the time to review our manuscript. We have highlighted the changes in our manuscript within the document by using colored (blue) text; deleted text is marked in red and crossed out. The information regarding page numbers refers to the previous version of the manuscript. The comments of the reviewer (RC) and the responds of the author (AC) are listed below.

Response to Reviewer 2

RC: 1. Line 79 take out word \"briefly\".

AC: 1. Thank you for this point; we have deleted it.

RC: 2a. Line 204 Did you really homogenize the cells in 70% ethanol (more likely aquaeous)?

AC: 2a. Thank you very much for your comment. We agree with your assessment and apologize for this mistake. We missed to incorporate that after the rehydration-step with 70% ethanol, we homogenized the cells in Target Retrievel Solution pH9 (\#S2367, Dako, Glostrup, Denmark). We rewrote the section "3D imaging of immunofluorescence-labeled isolated nuclei" and added it as a separate laboratory protocol with its own identifier (DOI) to our manuscript (<http://dx.doi.org/10.17504/protocols.io.78phrvn>).

RC: 2b. Also, cells should not have needed permeabilization since they went through xylene.

AC. 2b. This is a very interesting point. We agree with you that permeabilization is not always needed as xylene interacts with the cell membrane and changes the permeability \[25, 26\]. Nevertheless, it is documented that the exact mechanism is not fully understood \[25\]. We are of the opinion that it also depends on the thickness of the tissue sections. To isolate complete nuclei, paraffin-embedded tissue sections were cut relatively thick (60 μm) to keep the nucleus intact as effectively as possible. In this case addition of xylene was performed to remove paraffin from the paraffin-embedded tissues. Since the mechanism of how xylene interacts with the cell membrane is not fully understood, we think it is better to add saponin to the Dako REAL Antibody Diluent (\#S2022, Dako) to ensure that the antibody penetrates the nucleus. However, regarding our double-labeling immunofluorescence studies of FFPE tissue sections cut at 1 μm, experiments were carried out according to standard protocols and we did not add saponin to the antibody dilution buffer (Dako REAL Antibody Diluent, \#S2022, Dako). In the troubleshooting data of abcam it is recommended if the antibody cannot penetrate the nucleus, where the protein is located (nuclear protein) to add a strong permeabilizing agent like Triton™ X-100 to the blocking buffer and antibody dilution buffer (<https://www.abcam.com/content/immunohistochemistry-the-complete-guide>). We permeabilized the cells with saponin according to a modified flow cytometry and cell sorting protocol \[27\]. We incubated the antibodies in the presence of saponin because it is documented that in contrast to many other detergents cell permeabilization with saponin is a reversible process and once saponin is removed from the sample, the pores of the membrane will be closed \[28\]. Saponin intercalates in the membrane structure, replacing cholesterol and leaves much of the membrane structure intact \[29--31\].

RC: 3. Line 318-19. The writing is not clear. I think you mean \"No other genes were mutated in more than one case\".

AC: 3. We agree that this part is unclear. Unfortunately, we cannot replace it by your words because we found for example in ARID1B gene the R1534K and R1552K mutations in 3 /107 (2.7 %) cases (supporting information S6 Table). These are mutations, which we did not want to discuss in our manuscript in more detail. For more openness and transparency, however, we have replaced the former text (line 318-19 of the previous manuscript) as follows: "We detected with a maximum of 3/107 (2.8%) cases a rather low incidence of mutations in the genes of the Wnt pathway and we did not find any associations between these mutations and the occurrence of NI."

RC: 4. Line 324. Not clear. I think you can delete the beginning of the sentence to say \"Lamin A/C positive inclusions occur most frequently\...\"

AC: 4. We have deleted the beginning of the sentence.

RC: 5. Line 389-390. I don\'t think you have any basis to speculate about the temporal aspects of the fate of inclusions. I would say something like \"as if it could become ejected soon\"

AC: 5. We agree with you and we have replaced the section "which seems to be pushed to the edge of the nucleus for being ejected soon." by "as if it could become ejected soon.\"

RC: 6. The authors may want to include this reference on intranuclear cytoplasmic inclusions:

Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A, Khan A. 2004. beta-Catenin expression in thyroid follicular lesions: Potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol 15:329-- 337.

AC: 6. We have added to the introduction section (line 99 of the previous manuscript): "In addition, it is also documented that strong immunopositivity for ß-catenin was detected within NI in 83% of PTCs \[32\]. "
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